Andreas Moser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andreas Moser has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ansgar Thümen
Neurochemical Research Group, Department of Neurology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
2 shared publicationsFatimunnisa Qadri
Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
2 shared publicationsA. Gänsle
1 shared publicationAnne Behnecke
Neurochemical Research Group, Department of Neurology, Medical University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
1 shared publication- Astrid Maass
Fraunhofer-Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, Germany
1 shared publication J. Scholz
1 shared publication
Latest Publications
- 1 December 2003
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 216 (1) , 109-112
Modulation of striatal serotonin and opioid receptor mRNA expression following systemic N-methyl-norsalsolinol administration
- 1 December 2003
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 216 (1) , 109-112
Modulation of striatal serotonin and opioid receptor mRNA expression following systemic N-methyl-norsalsolinol administration
- 24 April 2003
- Published by Elsevier in Neuroscience Letters
- Vol. 341 (1) , 57-60
Deep brain stimulation: response to neuronal high frequency stimulation is mediated through GABAA receptor activation in rats
- 24 April 2003
- Published by Elsevier in Neuroscience Letters
- Vol. 341 (1) , 57-60
Deep brain stimulation: response to neuronal high frequency stimulation is mediated through GABAA receptor activation in rats
- Open Access
- 1 March 2003
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 6 (1) , 35-40
N-methyl-norsalsolinol modulates serotonin metabolism in the rat caudate nucleus: correlation with behavioural changes
In earlier studies the dihydroxylated tetrahydroisoquinoline derivative 2(N)-methyl-norsalsolinol (NMNorsal) was identified in patients with Parkinson's disease. In the present study, NMNorsal (20 or 40 mg/kg) was given intraperitoneally to rats kept under normal light–dark cycles. Using brain microdialysis technique, serotonin (5-HT), 5-hydroxyindolacetic acid (HIAA), dopamine (DA), and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined in the dialysate from caudate nucleus in vivo and from tissue in vitro at various times following NMNorsal administration. Even after high-dose NMNorsal administration (40 mg/kg) and measurements up to 48 h after administration, levels of DA and its metabolite DOPAC were not modified. In contrast to the DA metabolism, 5-HT levels in the dialysate increased to approx. 2-fold during the 48 h following administration of a single high-dose of NMNorsal while HIAA decreased to approx. 50%. These changes of 5-HT and HIAA were nearly identical in the homogenate preparation of the caudate nucleus when compared to the amounts present in the dialysate. During assessment controls and low-dose-treated animals were almost always sleeping. Only high-dose NMNorsal-treated rats were active, with maximum activity after 48 h, however, behavioural activity was clearly different to the classical 5-HT behavioural syndrome. Taken together, increased 5-HT levels in the striatum found in our studies seem to be linked to the behavioural activity induced by high-dose NMNorsal, and NMNorsal appeared to perturb normal diurnal rhythms of spontaneous locomotor activity. The precise mechanism by which NMNorsal acts on 5-HT metabolism and behaviour is, however, unclear and further investigation is required.
- 1 March 2003
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 6 (1) , 35-40
Open AccessN-methyl-norsalsolinol modulates serotonin metabolism in the rat caudate nucleus: correlation with behavioural changes
In earlier studies the dihydroxylated tetrahydroisoquinoline derivative 2(N)-methyl-norsalsolinol (NMNorsal) was identified in patients with Parkinson's disease. In the present study, NMNorsal (20 or 40 mg/kg) was given intraperitoneally to rats kept under normal light–dark cycles. Using brain microdialysis technique, serotonin (5-HT), 5-hydroxyindolacetic acid (HIAA), dopamine (DA), and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined in the dialysate from caudate nucleus in vivo and from tissue in vitro at various times following NMNorsal administration. Even after high-dose NMNorsal administration (40 mg/kg) and measurements up to 48 h after administration, levels of DA and its metabolite DOPAC were not modified. In contrast to the DA metabolism, 5-HT levels in the dialysate increased to approx. 2-fold during the 48 h following administration of a single high-dose of NMNorsal while HIAA decreased to approx. 50%. These changes of 5-HT and HIAA were nearly identical in the homogenate preparation of the caudate nucleus when compared to the amounts present in the dialysate. During assessment controls and low-dose-treated animals were almost always sleeping. Only high-dose NMNorsal-treated rats were active, with maximum activity after 48 h, however, behavioural activity was clearly different to the classical 5-HT behavioural syndrome. Taken together, increased 5-HT levels in the striatum found in our studies seem to be linked to the behavioural activity induced by high-dose NMNorsal, and NMNorsal appeared to perturb normal diurnal rhythms of spontaneous locomotor activity. The precise mechanism by which NMNorsal acts on 5-HT metabolism and behaviour is, however, unclear and further investigation is required.
- Open Access
- 1 March 2003
- Published by Wiley in European Journal of Biochemistry
- Vol. 270 (6) , 1065-1075
Modeled ligand-protein complexes elucidate the origin of substrate specificity and provide insight into catalytic mechanisms of phenylalanine hydroxylase and tyrosine hydroxylase
- 1 March 2003
- Published by Wiley in European Journal of Biochemistry
- Vol. 270 (6) , 1065-1075
Open AccessModeled ligand-protein complexes elucidate the origin of substrate specificity and provide insight into catalytic mechanisms of phenylalanine hydroxylase and tyrosine hydroxylase
- 1 December 1999
- Published by Elsevier in Neuropeptides
- Vol. 33 (6) , 492-497
Pituitary adenylate cyclase-activating polypeptide (PACAP-27) enhances tyrosine hydroxylase activity in the nucleus accumbens of the rat
- 1 December 1999
- Published by Elsevier in Neuropeptides
- Vol. 33 (6) , 492-497
Pituitary adenylate cyclase-activating polypeptide (PACAP-27) enhances tyrosine hydroxylase activity in the nucleus accumbens of the rat